Request Demo
Evommune drops IRAK4 inhibitorIRAK4 inhibitor after assessing phase 2 dermatitis data
Phase 2
Evommune completed a phase 2 study of EVO101 in adults with mild to moderate atopic dermatitis.
Evommune has dropped its only clinicalEVO101 asset after reviewing data from atopic dermatitisn atopic dermatitis.
The California-based biotech made the decision to discontinue the interleukin 1 receptor-associaatopic dermatitisK4) inhibitor dubbed EVO101 after considering the results of the midstage study in adults with mild to moderate atopic dermatitis.
"We executed a robust and well-controlled phase 2a study of EVO101interleukin 1 receptor-associated kinase 4 (IRAK4) inhibitorinterleukin 1 receptor-associated kinase 4 (IRAK4)ndard of care, andEVO101allowed us to make an efficient decision based on the data," CEO Luis Peña said in thatopic dermatitise.
IRAK4 continues to be a target of interest for pharma. GileaEVO101nces handed over $20 million upfront in March to license an IRAK4 degrader from Nurix only a month after the Big Pharma dropped two of the three indications being explored for its IRAK4 inhibitor called GS-5718.
IRAK4EVO101 out of the picture, Evommune will “focus itGilead Sciencesadvancing its pipeline of systemically administered prodIRAK4andidates whichNurix multiple milestones expected over the next several years.”IRAK4 inhibitorIRAK4GS-5718
TheseEVO101dates include EVO756,EvommuneRX2 antagonist being developed for urticaria and interstitial cystitis. Evommune said the candidate has the potential to be a first-in-class oral treatment for “a variety of mast cell mediated disease, as well as diseases involving sensory neuron mediated cutaneous itch.”
With the biotech sharing EVO756to laMRGPRX2 antagonisthe clinic in early 20urticariao hasinterstitial cystitisal. The company has licensed the rights to develop and commercialize the asset in Japan for a total of $mast cell mediated diseaseront and potential milestone paysensory neuron mediated cutaneous itchse.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.